C THE S!GNS
DEAD

Serial Number

97235079

Owner

C the Signs Limited

Attorney

Mary Margaret L. O'Donnell

Filing Date

Jan 24, 2022

Add to watchlist:

No watchlists yet
View on USPTO

C THE S!GNS Trademark

Serial Number: 97235079

C THE S!GNS is a trademark filed by C the Signs Limited on January 24, 2022. The trademark is classified under Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

C the Signs Limited (5 trademarks)

1-7 Harley Street
London W1G9QD , GB

Entity Type: 99

Trademark Details

Filing Date

January 24, 2022

Registration Date

Not Registered

Published for Opposition

July 18, 2023

Goods & Services

(Based on 44(e)) Educational and training services relating to healthcare, namely, conducting training, workshops, classes in the field of healthcare; (Based on Intent To Use) education services, namely, conducting training, workshops, classes in the field of healthcare; providing of training in the field of cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients, rendered through correspondence courses; teaching in the field of cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients; arranging and conducting of conferences, seminars and training workshops in the field of cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients; providing education in the field of cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients rendered through correspondence courses; educational services, namely, conducting classes, workshops, seminars in the field of cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients; vocational guidance; organisation of exhibitions for educational purposes; providing on-line electronic publications in the nature of books, magazines, brochures, leaflets in the field of cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients; information, advisory and consultancy services relating to all of the aforesaid; all of the aforesaid services relating only to assessing cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients and none of the aforesaid relating to the testing and screening of neurological conditions

(Based on 44(e)) Downloadable artificial intelligence software for healthcare for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; (Based on Intent To Use) downloadable software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; downloadable software applications for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; downloadable application software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; downloadable computer software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; downloadable smartphone software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; computer software platforms, recorded or downloadable for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; downloadable mobile application software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; digital media, namely, downloadable audio and audiovisual recordings featuring information and advice relating to cancer risk, cancer diagnosis, cancer treatment and the clinical needs of patients; multi-platform digital tools, namely, downloadable software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; all of the aforesaid goods for use in relation to and relating only to assessing cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients and none of the aforesaid relating to the testing and screening of neurological conditions

(Based on 44(e)) Data processing services in the field of healthcare; (Based on Intent To Use) data management, namely, database management, computer data entry services; data processing services; database management; computer data entry services and data processing services; compilation of data for business purposes; automated data processing services; electronic data collection services for business purposes in the fields of medicine and healthcare; systematization of data in computer databases; collating of data in computer databases, namely, compilation and systemization of information into computer databases; market research data analysis; online data processing services; preparation of healthcare statistical data, namely, providing statistical healthcare information for business or commercial purposes; dissemination of data relating to healthcare, namely, providing business information in the field of healthcare, database processing services; data and database improvement, namely, updating and maintenance of data in computer databases; data and database enhancement, namely, updating and maintenance of data in computer databases; combining data from multiple sources into databases, namely, systemization of data in computer databases; information, advisory and consultancy services relating to all of the aforesaid; all of the aforesaid services relating only to assessing cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients and none of the aforesaid relating to the testing and screening of neurological conditions

(Based on 44(e)) Healthcare; medical services; hospital services and medical clinics; medical assistance; nursing services; health screening services in the field of cancer; medical information; health care services in the nature of dissemination of data relating to healthcare, namely, providing a database in the field of cancer information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; all of the aforesaid services relating only to assessing cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients; advisory and consultancy services relating to all of the aforesaid and none of the aforesaid relating to the testing and screening of neurological conditions

(Based on 44(e)) Information technology services for the pharmaceutical and healthcare industries, namely, providing information technology consulting services, and providing temporary use of online non-downloadable software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; (Based on Intent To Use) providing online, non-downloadable software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; software as a service (SaaS) services featuring software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; platform as a service (PaaS) services featuring computer software platforms for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; providing online, non-downloadable software platforms for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; providing online, non-downloadable software, software as a service (SaaS) services featuring software, platform as a service (PaaS) services featuring computer software platforms and online, non-downloadable software platforms all for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; information, advisory and consultancy services relating to all of the aforesaid; providing temporary use of online non-downloadable artificial intelligence software for healthcare for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; providing temporary use of online non-downloadable software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; providing temporary use of online non- downloadable software applications for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; providing temporary use of online non-downloadable application software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; providing temporary use of online non-downloadable computer software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; providing temporary use of online non-downloadable smartphone software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; providing temporary use of online non-downloadable mobile application software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; multi-platform digital tools, namely, providing temporary use of online non-downloadable software for assessing cancer risk, diagnosing cancer, treating cancer and assessing the clinical needs of cancer patients; compilation of data, namely, compiling data for research purposes in the field of medical science and medical consultancy; database improvement, namely, maintenance of on-line databases for others; database enhancement, namely, maintenance of on-line databases for others; all of the aforesaid services relating only to assessing cancer risk, cancer diagnosis, cancer treatment and assessing the clinical needs of cancer patients and none of the aforesaid relating to the testing and screening of neurological conditions

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Oct 13, 2025 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Oct 13, 2025 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 5, 2025 EXRA
SOU EXTENSION 3 GRANTED
Feb 4, 2025 EX3G
SOU EXTENSION 3 FILED
Feb 4, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 4, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 9, 2024 EXRA
SOU EXTENSION 2 GRANTED
Sep 9, 2024 EX2G
SOU EXTENSION 2 FILED
Sep 9, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 9, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 28, 2024 EXRA
SOU EXTENSION 1 GRANTED
Feb 27, 2024 EX1G
SOU EXTENSION 1 FILED
Feb 27, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 27, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 12, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 18, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jul 18, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 28, 2023 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 14, 2023 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 2, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Jun 2, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 2, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Jun 2, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 2, 2023 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 2, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 1, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 1, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 1, 2023 GNRN
NON-FINAL ACTION E-MAILED
Feb 1, 2023 GNRT
NON-FINAL ACTION WRITTEN
Feb 1, 2023 CNRT
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jan 5, 2023 AMPX
ASSIGNED TO LIE
Jan 4, 2023 ALIE
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 8, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 8, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 8, 2022 CNRT
TEAS VOLUNTARY AMENDMENT RECEIVED
Nov 7, 2022 PARI
ASSIGNED TO EXAMINER
Nov 2, 2022 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 28, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 27, 2022 NWOS
NEW APPLICATION ENTERED
Jan 27, 2022 NWAP